Charles River Laboratories is investing $500 million to promote the values of the 3Rs minimization of animal testing across its business. The Alternative Methods Advancement Project, launched in April, will receive $300 million over the next five years, adding to an initial $200 million invested so far by the contract research organization (CRO). The aim is to boost the implementation of 3Rs —replacement, reduction and refinement — in drug testing by developing animal-free methods for drug discovery and development. The CRO is also seeking partnerships to advance the use of virtual datasets and historical studies that can provide predictive information while reducing the use of animals.

The principles of the 3Rs for the humane and ethical use of animals in research were developed over 50 years ago and have been put into practice in scientific research and embedded in national and international legislation. In industry, advances in applying the 3Rs have been most effective in cosmetics testing. As a CRO, Charles River is exploring ways to enhance the implementation of 3Rs in drug development.

Charles River Laboratories 正在投资 5 亿美元，以在其整个业务中推广 3R 最小化动物测试的价值。替代方法推进项目于 4 月启动，在合同研究组织 (CRO) 迄今为止初始投资的 2 亿美元基础上，将在未来五年内获得 3 亿美元。其目的是通过开发药物发现和开发的非动物方法来促进药物测试中 3R（替代、减少和改进）的实施。 CRO 还在寻求合作伙伴关系，以推进虚拟数据集和历史研究的使用，这些数据集和历史研究可以提供预测信息，同时减少动物的使用。

在研究中人道和合乎道德地使用动物的 3R 原则是 50 多年前制定的，并已在科学研究中付诸实践，并纳入国家和国际立法。在工业界，3R 应用的进步在化妆品测试中最为有效。作为 CRO，Charles River 正在探索加强药物开发中 3R 实施的方法。